Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02704-x)

Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian ZohrenNeeraj Agarwal

    Research output: Contribution to journalComment/debate

    2 Citations (Scopus)

    Abstract

    Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02704-x, published online 4 December 2023. In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.

    Original languageEnglish
    Pages (from-to)1505
    Number of pages1
    JournalNature Medicine
    Volume30
    Issue number5
    DOIs
    Publication statusPublished - 1 May 2024

    Cite this